Publication: ONdrug Delivery 180, 26th November 2025

Abstract: With the increasing demand for new inhalation therapies, the need for efficient, patient-centric and sustainable delivery platforms is paramount. The Resyca PFSI is uniquely positioned to meet these needs, enabling precise and reliable delivery of even the most fragile molecules.

Soft Mist Inhaler (SMI) technology is transforming inhaled drug delivery — making treatments more efficient, patient-friendly, and sustainable.

Key highlights from the article:

• Enhanced Usability: SMIs reduce coordination errors and improve lung deposition, supporting better outcomes for diverse patient groups.
• Compatibility with Biologics: Ideal for next-generation therapies like vaccines and gene therapies, where gentle aerosolisation is crucial.
• Innovation with PFSI™: Resyca’s Pre-Filled Syringe Inhaler sets new standards for precision dosing, scalability, and patient-centric design. PFSI – Soft Mist Inhaler SMI.

This innovation is paving the way for tailored dosing, improved treatment adherence, and cost-effective delivery—critical for biologics and high-value therapies.

The post Enhancing drug delivery with innovative soft mist inhaler technology first appeared on Resyca.

Publication: Drug Development & Delivery, Volume 24(7), 2024

Abstract: Worldwide, rising cases of chronic lung conditions, such as asthma, cystic fibrosis, pulmonary arterial hypertension (PAH), and chronic obstructive pulmonary disease (COPD), are driving demand for inhalation drug delivery devices.

As respiratory diseases rise and biologics rapidly expand, the need for advanced, patient-friendly delivery solutions is accelerating. This article explores how Soft Mist Inhaler (SMI) technology is opening new pathways for inhaled and nasal biologics – from improving dosing performance to reducing reliance on needle-based administration.

By reading our article, you’ll discover:

• Why inhalation and nasal delivery are becoming strategic routes for biologics.
• How reformulation into inhaled or nasal formats can extend product life cycles.
• The key challenges of delivering sensitive biologics — and how soft mist technology overcomes them.
• The critical role of industry partnerships in accelerating device innovation and development efficiency.

Download the full article to find out more.

The post How soft mist inhalers support improved biopharma drug delivery first appeared on Resyca.

Publication: International Pharmaceutical Industry, Volume 16(1), 2024

Abstract: Biologics are reshaping modern healthcare, yet their full potential is often constrained by traditional administration routes. Recent advances in nasal inhalation, particularly soft mist nasal spray technologies, are redefining what is possible for sensitive biopharmaceutical formulations.

The rapid growth of both inhalation technologies and the global biologics market is creating new opportunities for patient-friendly, non-invasive drug delivery. Nasal inhalation and especially soft mist nasal spray technology, is emerging as a strong alternative to traditional parenteral routes, offering fast systemic uptake, improved patient experience, and expanded access beyond clinical settings.

However, biologics bring unique development challenges, including formulation sensitivity and the need for precise, consistent nasal deposition. Resyca’s next-generation soft mist nasal spray platforms address these barriers through biologic-compatible nozzle designs, controlled plume characteristics, and device architectures that minimise formulation stress while enhancing delivery efficiency.

As patent expiries accelerate competition in the biologics sector, nasal reformulation becomes a strategic path to lifecycle extension. Soft mist nasal sprays enable developers to differentiate existing products, streamline regulatory pathways, and unlock new therapeutic potential, positioning nasal delivery as a pivotal innovation for the next era of biopharmaceuticals.

Download

The post Transforming the biologics product lifecycle with inhalation innovation first appeared on Resyca.

Publication: International Pharmaceutical Industry, Volume 14(2), 2022

Abstract: The COVID-19 outbreak has provided a number of lessons for the pharmaceutical industry to consider for future pandemics. Could soft mist inhalers (SMIs), and soft mist nasal sprays in particular, hold the key to improved vaccine delivery?

Biologic vaccines are highly sensitive, and conventional nasal devices can compromise formulation integrity or fail to deliver consistent doses. Next-generation soft mist inhalers (SMIs) and soft mist nasal sprays address these challenges through controlled plume dynamics, narrow spray cone angles, and biologic-compatible nozzle designs that enhance deposition in the upper nasal cavity while minimising particle damage.

Built on modular, standardised platforms, these devices also streamline development, reduce customisation needs, and support faster regulatory and commercialisation timelines. As a result, SMIs and soft mist nasal sprays offer a practical, scalable route to unlocking the full potential of nasal vaccines—strengthening global preparedness and enabling more efficient, accessible vaccination strategies for future pandemics.

Find out more in our article.

The post SMIs & Soft Mist Nasal Sprays – A key defence in the fight against the next pandemic? first appeared on Resyca.

Publication: OnDrug Delivery, No 131, April 11th 2022

Abstract: The rise of the biopharmaceutical segment has increased the value of the inhalation sector, with more and more drug developers exploring inhalation as an alternative delivery mechanism to the parenteral approach traditionally used for biologics.

While inhalation is an ideal delivery pathway for a wide range of drugs, pharmaceutical companies face a range of challenges when developing effective inhalation drug products.

In fact, the cost and complexity of developing and customising inhalation devices and formulations are often too high for biologics or drug products requiring large dosages.

Soft mist inhaler (SMI) technology has evolved in recent years alongside traditional inhalation device technologies with a range of different technical capabilities. Does SMI technology offer the opportunity to address this issue and support the expansion of the inhalation segment?

Download

The post Do soft mist inhalers hold the key to faster inhalation drug development? first appeared on Resyca.